StockNews.AI
LTRN
StockNews.AI
106 days

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

1. LTRN received FDA clearance for Phase 1b/2 trial of LP-184. 2. Approval boosts regulatory momentum for LTRN's cancer therapy developments.

2m saved
Insight
Article

FAQ

Why Very Bullish?

FDA clearance typically leads to increased investor confidence and potential revenue. Similar approvals in biotech have historically spurred significant stock price increases.

How important is it?

FDA clearance is critical for LTRN's drug pipeline and future revenue potential.

Why Long Term?

Positive FDA news can enhance future clinical trial funding and partnerships, affecting LTRN's market position over time.

Related Companies

AMGNMRKBMY
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that it has received clearance of its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial for LP-184 in Triple Negative Breast Cancer. This achievement builds on the previous regulatory momentum including Orphan Drug.

Related News